Ex-Cel­gene chief Mark Alles, for­mer Goldfinch Bio leader Tony John­son are back in the game as CEOs

→ For the first time since he sold Cel­gene to Bris­tol My­ers Squibb for $74 bil­lion in 2019, Mark Alles is a CEO again. Alles had been chair­ing the board at TORL Bio­ther­a­peu­tics, an an­ti­body mak­er from UCLA’s Den­nis Sla­m­on, and will now pace the side­lines as CEO of the com­pa­ny. Since the Cel­gene buy­out, Alles has shown up oc­ca­sion­al­ly in Peer Re­view by tak­ing board ap­point­ments, in­clud­ing the role of chair­man at AI Pro­teins, Wu­gen and Turn­ing Point Ther­a­peu­tics, which al­so caught the eye of Bris­tol My­ers. Look­ing to cash in on the an­ti­body-drug con­ju­gate craze, TORL launched last April and nabbed $158 mil­lion in Se­ries B fi­nanc­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER